What Happened
- US President Donald Trump signed an executive order imposing a 100% ad valorem tariff on imports of patented pharmaceutical products from countries that have not entered a "reshoring agreement" with the US Commerce Department or a "Most Favoured Nation" pricing deal with the Department of Health and Human Services.
- India's Global Trade Research Initiative (GTRI) assessed that India is "more or less shielded" from the worst effects because India's pharmaceutical exports to the US are overwhelmingly generic drugs — which are explicitly exempted from the executive order.
- Generic drugs, biosimilars, and associated active pharmaceutical ingredients (APIs) are excluded from the tariff, providing a significant buffer for India.
- Countries including the European Union, Japan, South Korea, and Switzerland face a lower 15% tariff rate after their major pharma companies signed reshoring and MFN agreements; the UK faces a 10% rate.
- Countries that have not signed such agreements — including India — face the full 100% tariff specifically on patented (branded) drugs, though India exports very few patented drugs to the US.
- The tariffs are to be implemented in phases: 120 days for large companies and 180 days for smaller ones, with implementation beginning July-September 2026.
Static Topic Bridges
India's Pharmaceutical Industry: The Generic Drug Advantage
India is the world's largest supplier of generic medicines by volume, providing approximately 20% of global generic drug supply. This structural position — built on a combination of reverse engineering capabilities, cost-efficient manufacturing, and a large pool of skilled chemists and pharmacists — means that India's pharma exports are almost entirely non-patented molecules. Generic drugs are chemically identical to branded originator drugs but sold at a fraction of the cost after patents expire.
- India supplied approximately 47% of generic prescription drugs dispensed in US pharmacies in 2022.
- India's pharmaceutical exports reached approximately USD 30.47 billion in FY2024-25; the US accounts for about 34% of these exports (~USD 9.7 billion).
- Key Indian pharma exporters to the US include Sun Pharma, Dr. Reddy's Laboratories, Lupin, Cipla, and Zydus Lifesciences.
- India supplies approximately 50% of US demand for generic drugs — including critical medicines for HIV/AIDS, tuberculosis, malaria, and cardiovascular disease.
- The Indian Patent Act, 2005 (amended to comply with TRIPS) prohibits "evergreening" through Section 3(d), which does not grant new patents for new forms of known substances unless significantly enhanced efficacy is shown — a provision that has shaped India's generic-friendly pharmaceutical landscape.
Connection to this news: Because India's entire pharma export relationship with the US is built on generics and biosimilars — which are explicitly exempted — the 100% tariff on patented drugs has minimal direct trade impact. The risk is indirect: investment decisions and future supply chain reconfiguration.
US Pharmaceutical Tariff Policy: The Reshoring Agenda
The Trump administration's pharmaceutical tariff executive order is part of a broader industrial policy aimed at reshoring drug manufacturing to the United States. During the COVID-19 pandemic, the US discovered dangerous dependencies on foreign-produced APIs (particularly from China and India) for critical medicines. The executive order operationalises a "sticks and carrots" approach — punishing foreign-produced patented drugs with tariffs while rewarding companies that commit to US manufacturing investment.
- The 100% tariff applies to patented pharmaceuticals and their associated pharmaceutical ingredients imported from countries that have not signed reshoring or MFN pricing agreements.
- Companies in signatory countries (UK, EU, Japan, South Korea, Switzerland) face lower 10-15% tariffs — suggesting those governments negotiated sector-level exemptions as part of broader trade deals.
- MFN (Most Favoured Nation) pricing in the pharma context means the US government negotiating drug prices at the lowest price offered to any other country — a longstanding demand of US health policy advocates.
- The Inflation Reduction Act (2022) had already introduced Medicare drug price negotiation in the US; the Trump executive order extends price pressure through tariff leverage.
Connection to this news: India's limited exposure to the 100% tariff is a function of its export mix — but the broader US policy direction signals that future tariff expansion to generics cannot be ruled out, particularly if US drug shortage concerns intensify or trade negotiations take a protectionist turn.
Most Favoured Nation Clause in Trade and Pharma Context
Most Favoured Nation (MFN) is a standard principle in international trade law (enshrined in GATT/WTO rules) requiring that a trade advantage offered to one country must be offered to all WTO members. In the pharmaceutical tariff context, however, the US is using MFN pricing in a different sense — requiring foreign pharma companies selling patented drugs to the US to offer prices no higher than what they charge in other developed markets.
- GATT Article I establishes the MFN principle; WTO membership obligates adherence.
- The Trump executive order's use of "MFN pricing" is a domestic health policy tool, not an international trade law obligation — it is about drug pricing, not import duties.
- India has consistently opposed pharmaceutical MFN pricing demands in trade negotiations, arguing they would undermine access to affordable generic medicines in developing countries by enabling pharmaceutical companies to raise global prices.
- Section 3(d) of India's Patents Act, 2005 remains a key protective instrument against patent extensions that could foreclose generic production.
Connection to this news: The MFN pricing mechanism in the executive order is designed to give US payers the same low drug prices that European health systems negotiate — countries whose pharma companies sign MFN deals get lower tariffs. India's generic-focused industry has no comparable incentive to sign such agreements, nor is India named as a target.
Key Facts & Data
- Tariff rate on patented drugs from non-signatory countries: 100% ad valorem.
- Tariff rate for EU, Japan, South Korea, Switzerland: 15% (post-reshoring/MFN agreements).
- Tariff rate for UK: 10%.
- Generics, biosimilars, and associated APIs: explicitly exempted from the executive order.
- India's pharmaceutical exports to the US: approximately USD 9.7 billion in FY2024-25.
- India supplies ~47% of generic prescriptions filled in US pharmacies.
- India's share of global generic drug supply by volume: approximately 20%.
- Implementation timeline: 120 days (large companies), 180 days (smaller companies); effective July-September 2026.
- GTRI (Global Trade Research Initiative) is an independent Indian trade research think tank.